Department of Cardiovascular Surgery, Bichat-Claude Bernard Hospital, 46, rue Henri-Huchard, 75018 Paris, France.
Department of Cardiovascular Surgery, Bichat-Claude Bernard Hospital, 46, rue Henri-Huchard, 75018 Paris, France.
Ann Cardiol Angeiol (Paris). 2020 Oct;69(4):204-206. doi: 10.1016/j.ancard.2020.07.013. Epub 2020 Aug 11.
Trans-catheter aortic valve implantation (TAVI) has recently emerged as a less invasive alternative to surgical aortic valve replacement (SAVR) in high risk patients. Although several procedures have been performed worldwide, infective endocarditis (IE) has been reported to be a rare TAVI complication, nevertheless if IE occurs it represents a life-threatening condition and treatment is challenging. TAVI-IE are thus normally treated conservatively by targeted antibiotic therapy with a high reported mortality (40%). Surgical explant represent the definitive strategy but, the intervention is at a high risk (risk of complication 87%, with an in hospital mortality of about 47%). In the present paper, we report the case of a 71-year-old patient affected by an early endocarditis after TAVI (TAVI-IE) treated at our Institution by surgical explant. The case highlights a paradox: if TAVI procedures are indicated over traditional surgical valve replacement in treatment of high surgical risk patients, what should be the best management when TAVI-IE occurs in these same population of patients?
经导管主动脉瓣植入术(TAVI)最近已成为高危患者外科主动脉瓣置换术(SAVR)的一种侵入性较小的替代方法。尽管已经在全球范围内进行了多项手术,但感染性心内膜炎(IE)是 TAVI 的罕见并发症,如果发生 IE,则代表危及生命的情况,治疗具有挑战性。因此,TAVI-IE 通常通过靶向抗生素治疗保守治疗,报告的死亡率较高(40%)。外科取出术是明确的治疗策略,但手术风险较高(并发症风险为 87%,住院死亡率约为 47%)。在本文中,我们报告了一例在我们机构接受治疗的 71 岁患者,该患者在 TAVI 后发生早期心内膜炎(TAVI-IE)。该病例突出了一个悖论:如果 TAVI 手术在治疗高手术风险患者中优于传统的外科瓣膜置换术,那么当 TAVI-IE 发生在这些相同的患者群体中时,最佳的治疗方法是什么?